236 results about "Serotype" patented technology

The invention relates to the technical field of molecular biology, in particular to an avian adenovirus serum type 4 colloidal gold test strip based on a monoclonal antibody and application of the test strip. According to the invention, two monoclonal antibodies (6B3 and 8G11) aiming at FAdV4 penton protein are successfully prepared through a hybridoma technology, and both the monoclonal antibodies show high titer and strong serotype specificity. Specific analysis proves that the two monoclonal antibodies can recognize 12 FAdV4 isolates from different sources, and do not have cross reaction with other FAdV serotypes or common poultry pathogens. According to the invention, through systematic optimization of key parameters, the detection sensitivity of the test strip is 7.81 * 10 < 4 > TCID50 / 0.1 mL, and the detection time is only 15 minutes. Clinical sample verification shows that compared with an ELISA method, the total coincidence rate is 98.6%.

The invention relates to a fusion protein, an immunogenic composition and a recombinant degenerate vaccine for preventing and treating infection of various pathogenic streptococci, as well as a molecular architecture design, application and the like. According to the invention, three immune antigens, namely an elongation factor Tu (Tuf), a molecular chaperone DnaK and an elongation factor G (fusA), are screened, and it is proved that fusion protein molecules of the three antigens can significantly inhibit tissue lesions caused by infection of different serotypes and different types of streptococci, have good immunogenicity, play roles in immune protection and effective prevention and treatment, and have good application prospects. The bacillus subtilis has the characteristics of broad-spectrum and high-efficiency prevention of streptococcus bacterial infection, and has a wide application prospect.

A bacteriophage for specifically lysing high-virulence capsular Klebsiella pneumoniae, pertaining to the field of microorganisms. The deposit number of the Klebsiella pneumoniae bacteriophage vB_kpnP_D39 is CCTCC NO: M 2024690. In the bacteriophage liquid formulation prepared on the basis of the bacteriophage, the working titer of the bacteriophage is greater than 1 × 109 PFU / mL. The bacteriophage has high specificity and can kill all high-virulence multidrug-resistant Klebsiella pneumoniae of K1, K2, and K57 capsular serotypes, with an adsorption efficiency of 99.60%. The bacteriophage exhibits a biofilm clearance rate of 47.4%-63.2% and a capsule clearance rate of 42.1%-60.6% against the high-virulence Klebsiella pneumoniae. The bacteriophage is expected to become a safe, non-toxic agent for the prevention, control, and treatment of high-virulence multidrug-resistant Klebsiella pneumoniae infections, or an antibiotic adjuvant.

The present disclosure relates to novel adeno-associated adenovirus (AAV) vectors comprising targeting peptides. More particularly, the present disclosure relates to an adeno-associated serotype 2 virus vector, AAV2, comprising a transgene encoding LIGHT wherein the viral capsid of the AAV2 vector comprises a targeting peptide that alters its tropism to target tumor endothelial cells; and a use of the carrier. The disclosure also relates to the use of said vectors in therapy, in particular in the treatment of cancer.

The process comprises providing a recombinant vaccine construct, wherein said construct comprises genetically modified Lactobacillus plantarum NC8 as a live vector; modifying the genetic structure of said Lactobacillus plantarum NC8 to express conserved Salmonella antigens, including PagN, SopE2, and FliC, anchored by a ptrk 892 backbone with a constitutive promoter, phosphoglycerate mutase (PGM); incorporating Signal Lp_2145 and cAM12 Anchor sequences into said genetic construct to enhance surface expression of recombinant proteins on Lactobacillus plantarum NC8; administering said recombinant vaccine orally to poultry, leveraging the probiotic properties of Lactobacillus plantarum NC8 for effective colonization of the poultry gastrointestinal tract; inducing a prolonged and intensified immune response by ensuring sustained high-level expression of target antigens through the utilization of the robust constitutive promoter, phosphoglycerate mutase (PGM); and optimizing immunogenicity through the surface expression of recombinant proteins on Lactobacillus plantarum NC8, fostering a robust and precisely targeted immune response.

The invention relates to the technical field of genetic engineering, in particular to Encapsulin fusion protein for expressing foot and mouth disease virus epitopes and application of the Encapsulin fusion protein in preparation of subunit vaccines. The invention discovers that different serotypes of foot-and-mouth disease virus antigen epitopes are inserted among the 62nd to 63rd positions, the 124 to 125th positions, the 138 to 139th positions and the 239th to 240th positions of amino acids of an Encapsulin protein fragment subjected to amino acid sequence modification, and / or the 62nd to 63rd positions, the 124 to 125th positions, the 138 to 139th positions and the 239th to 240th positions of amino acids are replaced by the different serotypes of foot-and-mouth disease virus antigen epitopes; efficient and soluble expression of a target antigen in escherichia coli can be realized, and protein cage nano antigen particles are successfully self-assembled; the protein nano antigen particle can induce a widely neutralized foot-and-mouth disease virus antibody, improves the immune efficacy, and has the potential of becoming a broad-spectrum multivalent vaccine for foot-and-mouth disease.

The invention discloses mannheimia haemolytica outer membrane vesicles as well as a preparation method and application thereof, and belongs to the technical field of bioengineering. The OMV is separated from Mh-5 strain culture supernatant through tangential flow ultrafiltration combined with an ultracentrifugation technology, and animal experiments prove that a high-level IgG / IgM antibody can be induced by intramuscular injection of 50 micrograms per mouse, expression of inflammatory factors such as IL-6 and TNF-alpha of the spleen is remarkably improved, the protection rate after challenge reaches 85.7%, and pathological damage is remarkably lighter than that of an inactivated vaccine group. According to the scheme provided by the invention, the problems of insufficient serotype coverage and antibiotic resistance in the prior art are solved, and a new strategy is provided for prevention and control of mannheimia haemolytica.

According to various aspects of this disclosure, the present disclosure relates to methods for reducing kidney inflammation, reducing kidney fibrosis, reducing oxidative stress in the kidney, preventing or reducing the likelihood of chronic kidney disease (CKD), treating or preventing acute kidney injury (AKI) or treating a kidney disease in a subject in need thereof comprising administering, e.g., intramuscularly, to the subject a recombinant adeno-associated virus (rAAV) vector, wherein the rAAV vector comprises a vector genome comprising a nucleotide sequence encoding a Fibroblast growth factor 21 (FGF21) or a functional fragment thereof and an AAV capsid (e.g., AAV1 serotype), optionally, wherein the subject does not suffer from diabetes.

The invention discloses a pasteurella phage PTP1APTYT15 as well as a composition, a kit and application of the pasteurella phage PTP1APTYT15, the pasteurella phage PTP1APTYT15 is preserved in Guangdong Microbial Culture Collection Center on September 10, 2025, the preservation number of the pasteurella phage PTP1APTYT15 is GDMCC NO: 66946-B1, and the pasteurella phage PTP1APTYT15 is classified and named as Pasteurella phage PTP1APTYT15. The pasteurella phage PTP1APTYT15 provided by the invention has the characteristics of high temperature resistance and alkali resistance, and can be used for cracking pasteurella of various serotypes. In addition, the bacteriophage is high in proliferation efficiency and high in splitting capacity, has no adverse effect on human or animal health, and has good biological safety.

The invention discloses a preparation method of a boiling antigen for vibrio parahaemolyticus serum agglutination. The preparation method comprises the following steps: selecting common serotype vibrio parahaemolyticus in monitoring for resuscitation; scraping a ring of placenta by using 10 mu L of an inoculating loop, dissolving the placenta in 1 mL of normal saline to prepare a bacterial suspension, and preparing 3 tubes of bacterial suspensions from each strain; boiling the bacterial suspension in boiling water for 1 hour, 45 minutes and 30 minutes respectively; and after boiling, centrifuging at 10000 rpm for 10 minutes, discarding the supernate, and reserving the precipitate as a boiling antigen for serum agglutination. The result shows that the agglutination accuracy after boiling for 1 hour is 100%, and the agglutination degree is 2 + or above; and no significant difference exists between 45 minutes of boiling and 1 hour of boiling, and no significant difference exists between 30 minutes of boiling. Compared with a high-pressure method, the method has the advantages that the operation time is shortened by 2-3 hours, special equipment certificates are not needed, and the method is suitable for daily detection and food poisoning traceability.

The invention relates to the technical field of immunology, in particular to a haemophilus parasuis disease mucosal vaccine as well as a preparation method and application thereof.The haemophilus parasuis disease mucosal vaccine comprises serum type 4 haemophilus parasuis H0040LV4 and serum type 5 haemophilus parasuis H0014LV5 which are preserved in the China Center for Type Culture Collection (CCTCC) on November 10, 2025 and numbered as CCTCC M 20252516 and CCTCC M 20252517; the bivalent haemophilus parasuis bivalent outer membrane vesicle vaccine prepared by secreting outer membrane vesicles has a good immune protection effect on serum type 4 and type 5 haemophilus parasuis, and compared with a control group, pathological changes of tissues such as lungs and livers of a vaccine immune group are obviously relieved. The vaccine has good immunogenicity, can stimulate comprehensive immune response, induce the organism to generate remarkable specific mucosal immunity, and simultaneously induce cellular immunity and humoral immunity response, and has a wide application prospect.

This invention belongs to the field of molecular biology detection technology, specifically relating to a primer and probe combination for detecting avian Salmonella based on the RAA-LFD method and its application, particularly to a primer and probe combination for detecting three avian serotypes of Salmonella: Salmonella pullorum, Salmonella enteritidis, and Salmonella typhimurium, based on the RAA-LFD method and its application. This invention designs different types of probes and primers targeting the genes of serotypes SP, SE, and STM of Salmonella. Using the primer and probe combination of this invention, rapid, sensitive, and specific detection of Salmonella serotypes and the three avian Salmonella serotypes SP, SE, and STM can be achieved, greatly shortening the detection cycle of avian salmonellosis and improving the detection efficiency and accuracy of avian salmonellosis.

The invention discloses a porcine circovirus type 2 and haemophilus parasuis bivalent inactivated vaccine and a preparation method thereof. According to the invention, a porcine circovirus strain, a haemophilus parasuis serum type 4 strain and a haemophilus parasuis serum type 5 strain which are epidemic in situ are respectively separated and obtained, and the microbial preservation numbers of the porcine circovirus strain, the haemophilus parasuis serum type 4 strain and the haemophilus parasuis serum type 5 strain are respectively CGMCC (China General Microbiological Culture Collection Center) No.47094, CGMCC No.46698 and The separated strain or bacterial strain is prepared into a bivalent inactivated vaccine, and lentinan is added in the vaccine preparation process to enhance the immune effect; a safety evaluation result shows that local or whole-body adverse reaction caused by the bivalent vaccine does not occur, so that the safety of the bivalent vaccine is good; the immune efficacy evaluation result of the bivalent vaccine shows that the bivalent vaccine can provide complete protection for animals aiming at the in-situ epidemic porcine circovirus, haemophilus parasuis serotype 4 and haemophilus parasuis serotype 5, and has good immune protection efficacy.

This invention discloses a method for preparing a bivalent inactivated vaccine against bovine Pasteurella multocida type A and B and hemolytic Mansicular disease, belonging to the field of vaccine technology. The invention involves isolating capsular serum Pasteurella multocida type A, Pasteurella multocida type B, and hemolytic Mansicular disease; separately expanding the culture of these bacteria, then inactivating and concentrating the bacterial suspensions, and resuspending them in PBS to prepare bacterial suspensions; and finally, mixing the Pasteurella multocida type A, Pasteurella multocida type B, and hemolytic Mansicular disease suspensions with aluminum hydroxide adjuvant to prepare the inactivated vaccine. This invention provides simultaneous prevention of two diseases—bovine fibrinous purulent pneumonia and bovine hemorrhagic septicemia—as well as bovine Mansicular disease through vaccine immunization. The vaccine demonstrates good safety, stable immunization efficacy, and a long duration of immunity.

The invention belongs to the technical field of molecular biology, and discloses a truncated outer membrane protein of klebsiella pneumoniae and application thereof. The invention provides an outer membrane protein Lol B of klebsiella pneumoniae, which can be used for immunizing to induce a protective antibody aiming at various serotypes of klebsiella pneumoniae and killing the klebsiella pneumoniae. Specifically, the outer membrane protein Lol B immune serum can efficiently kill Klebsiella pneumoniae, and when a mouse immunized by the outer membrane protein Lol B immune serum is attacked by K1, K2 and K6 serotype Klebsiella pneumoniae, the mouse can be completely protected to survive, and the trend of weight loss of the mouse is remarkably reduced. Therefore, the outer membrane protein Lol B provided by the invention has a clinical application value for preventing and treating klebsiella pneumoniae infection.

This invention relates to the packaging and screening of viral vectors, particularly to the packaging and screening of AAV mutants, specifically an adeno-associated virus mutant that efficiently infects HT-22 cells. By constructing a peptide mutant library of AAV9, a new AAV9 mutant with seven inserted amino acids was obtained through screening and verification. This mutant can effectively infect HT-22 cells at an MOI of 1E+5, achieving a higher infection rate than the natural AAV9 serotype at MOI=1E+5. The AAV9-HT01 mutant obtained after screening showed the best effect, with a significantly higher infection positivity rate compared to the control AAV9 serotype under the same MOI conditions. The fold increase was 4.4-fold as measured by luciferase (RLU) value detection. This effectively reduces the amount of AAV cells used for infection, saving experimental costs, and simultaneously makes it feasible to study the mechanisms of gene therapy for central nervous system diseases in HT-22 cells.

The invention discloses a bivalent subunit vaccine for preventing infection of haemophilus parasuis and porcine circovirus type 2. A core antigen combination of the vaccine comprises at least one antigen protein from haemophilus parasuis, and the antigen protein is selected from Ferrin, OppA and Hem-SAP and is combined with a porcine circovirus type 2 Cap protein. Wherein the NCBI (National Center of Biotechnology Information) login number of the Ferrin, the NCBI login number of the OppA and the NCBI login number of the Hem-SAP are WP160414389.1, ACL32731.1 and WP035493594.1 respectively. The antigen protein is subjected to codon optimization, is expressed and purified through a prokaryotic expression system, and is emulsified with ISA201 or a Freund's adjuvant to prepare the vaccine. Animal experiments prove that the vaccine can excite high-level antigen specificity IgG, cell factors IFN-gamma and white IL-4 in an immune animal body, namely, specific Th1 and Th2 type immune responses are generated. The vaccine can generate an immune protection rate of up to 80% when attacked by a serum type 5 haemophilus parasuis virulent strain, and generates an effective antibody response to the porcine circovirus type 2. The vaccine provided by the invention has the advantages of definite components, good safety and strong immune protection force.

The invention discloses a salmonella bacteriophage combination and application thereof, and relates to the technical field of microorganisms. The salmonella bacteriophage combination is prepared from a bacteriophage BPLT2, a bacteriophage BP13076 and a bacteriophage BPSCBS, the bacteriophage BPLT2, the bacteriophage BP13076 and the bacteriophage BPSCBS are preserved in the China Center for Type Culture Collection on June 24, 2025, the preservation address is Wuhan University, Wuhan, China, and the preservation numbers are CCTCC NO: M 20251473, CCTCC NO: M20251472 and CCTCC NO: M 202514721 respectively. The bacteriophage combination can effectively split multiple different serotypes of salmonella and is not easy to induce the generation of bacteriophage resistance in the repeated use process.

The invention discloses a cryptococcus capsular polysaccharide detection kit. The cryptococcus capsular polysaccharide detection kit comprises a biotin-labeled cryptococcus monoclonal antibody and an acridinium ester-labeled cryptococcus monoclonal antibody, wherein the biotin-labeled cryptococcus monoclonal antibody and the acridinium ester-labeled cryptococcus monoclonal antibody are coupled with streptavidin magnetic beads. According to the cryptococcus capsular polysaccharide detection kit disclosed by the invention, the biotin-labeled cryptococcus monoclonal antibody coupled with the streptavidin magnetic beads and the acridinium ester-labeled cryptococcus monoclonal antibody are matched, so that the cryptococcus capsular polysaccharide detection kit has relatively strong recognition capability on various serotypes of cryptococcus, and the antibodies do not interfere with one another; according to the cryptococcus capsular polysaccharide detection kit, the detection sensitivity and the detection accuracy can be greatly improved, the problem that a detection result is greatly influenced by subjective consciousness and is inaccurate due to the fact that an existing detection method only depends on visual inspection is solved, and the cryptococcus capsular polysaccharide detection kit is convenient to operate, facilitates automatic operation of an instrument and reduces manual errors.

To provide AAV having modified transduction ability, the AAV including in its structure, various kinds of transducing genes including a clinically important transducing gene for a patient who requires a transducing gene.SOLUTION: There are provided: an isolation modification VP1 protein of an adeno-associated virus serotype 5 (AAV5) capsid, including one or more amino acid replacements for improving transduction efficiency, relative to VP1 protein of a wild type AAV5 capsid; and capsid and vector based on the isolation modification VP1 protein.SELECTED DRAWING: None

Provided herein are multiepitope peptides comprising at least one mucin 1 (MUC1) peptide, having MHC affinity for at least one HLA serotype, and recognized by CD4+ T cell receptors and / or CD8+ T cell receptors. Also provided herein are compositions comprising the multiepitope peptides and a cationic lipid, including vaccine compositions. In various embodiments, the cationic lipid is R-DOTAP. The present invention also provides methods of using the multiepitope peptides, as well as compositions and vaccine compositions. These methods of use include methods for treating cancer in a subject and methods for inducing MUC-specific polyfunctional and cytolytic T cell responses in a subject.

The invention relates to methods for detecting the presence or absence of an enterohemorrhagic Escherichia coli (EHEC) in a sample and / or identifying said EHEC. The invention further relates to such methods comprising subjecting the sample or protein therein to mass spectrometry to obtain mass spectrometry data, comparing the obtained mass spectrometry data with reference data for at least one EHEC strain with a specific serotype and optionally one or more non-EHEC strains and detecting the presence or absence of the EHEC.

The invention is directed to cocktails of different antibodies and methods of treating a patient. Antibodies of the collection are specifically reactive to different viral serotypes or species. Cocktails may comprise monoclonal antibodies with one or more having an extended half-life. For treating or preventing viral infections, cocktails may comprise antibodies against conserved regions of HA, NA and M proteins of influenza virus and / or conserved regions of S, M, E, P, N or NS proteins of coronavirus. Monoclonal antibody combinations enhance phagocytosis and killing of viruses by phagocytic cells, and enhance clearance of the infecting virus from the blood.

The invention discloses a multiplex fluorescent quantitative PCR (Polymerase Chain Reaction) kit and application thereof. According to the invention, a multiplex fluorescent quantitative PCR (Polymerase Chain Reaction) detection method for detecting serotype 4h listeria monocytogenes, other listeria monocytogenes and listeria ivanovii is established through the design of primers of specific plcB and i-inlE and a double-labeled probe. According to the multiplex fluorescent quantitative PCR detection method, 4h L of listeria monocytogenes, other listeria monocytogenes and listeria ivanovii infection of serum can be distinguished, and the pathogenic bacteria in food can be quantitatively detected. According to the method, the constructed specific recombinant plasmid is used as a positive quantitative standard substance, absolute quantification of target nucleic acid is achieved through a standard curve, and the method has the advantages of being convenient to operate, high in specificity, high in sensitivity, good in repeatability and the like; the method is suitable for rapid qualitative and quantitative detection of listeria monocytogenes and listeria ivanovii in clinical, food and environmental samples.

The invention provides a whole genome capture kit suitable for four types of dengue virus and application, the whole genome capture kit comprises two groups of primer pools, primers in the first primer pool comprise targeting primers with primer sequences shown as SEQ ID NO.1-SEQ ID NO.22, primers in the second primer pool comprise targeting primers with primer sequences shown as SEQ ID NO.22, and primers in the third primer pool comprise targeting primers with primer sequences shown as SEQ ID NO.22; a primer in the second primer pool contains a target primer of which the primer sequence is shown as SEQ ID NO.41. Reverse transcription and enrichment amplification of the dengue virus whole genome can be carried out in nucleic acid samples extracted from blood, throat swab and infected tissue environments, and the dengue virus detection kit can be used for detecting and identifying the dengue virus. And a powerful technical means can be provided for evolution analysis, molecular epidemiological research and scientific prevention and control of the dengue virus.

The invention belongs to the technical field of monoclonal antibodies, and particularly relates to a PPRV HN-targeted monoclonal antibody and application thereof. The PPRV HN-targeted monoclonal antibody is characterized by comprising a light chain and a heavy chain, and the amino acid sequence of a variable region of the light chain comprises QSIVHSSGNTY, KYS and FQGSHVPYT. And the amino acid sequences of the variable region of the heavy chain comprise GFNIKDYY, IDPENGYT and AELGRGSY. The monoclonal antibody provided by the invention provides a new effective tool and solution for veterinary detection, diagnosis, prevention and treatment of the PPRV serotype.

Provided is an RNA editing system activating a Wnt signaling pathway, relating to the field of gene editing. Provided is an RNA editing element, comprising an Axin1-targeting RNA fragment and an Axin2-targeting RNA fragment. A gRNA that targets both Axin1 and Axin2 is constructed, which, compared with gRNAs targeting Axin1 or Axin2 alone, can significantly up-regulate Wnt activity. An AAV6 vector is screened from three AAV vectors of different serotypes, and exhibits relatively high expression intensity and efficiency and high infection efficiency with respect to airway epithelial cells and alveolar epithelial cells while exhibiting very low infection efficiency with respect to immune cells and endothelial cells. The AAV vector is assembled with a Cre-LoxP recombinase system to together infect a host cell, thereby facilitating the measurement of Cas13d knockdown efficiency by means of fluorescent labeling.

Herein is reported a nucleic acid encoding a functional adeno-associated virus Rep protein, characterized in that the nucleic acid comprises in 5′- to 3′-direction a first 5′-terminal part, a second 5′-terminal part, a central part, a second 3′-terminal part and a first 3′-terminal part, wherein the first 5′-terminal part is similar to a part of the rep gene of the AAV2 or AAV6 serotype and a second 5′-terminal part is similar to a part of the rep gene of an AAV1 serotype and the second 3′-terminal part is similar to a part of the rep gene of the AAV10 or AAV11 serotype and a first 3′-terminal part is similar to a part of the rep gene of an AAV13 serotype.

To conduct detection of Salmonella, serotype transversely and specifically relative to other strains.SOLUTION: A heat-killed bacterial cell of Salmonella and antigen liquid containing an adjuvant are inoculated in a BALB / c mouse. After the inoculation, splenocytes or lymph node cells of the mouse and P3U1 are fused to prepare a hybridoma, and therefrom, a hybridoma for producing a monoclonal IgG antibody showing Salmonella specificity is selected, whereby three hybridomas for producing superior Salmonella specific antibodies are successfully acquired. Next, these monoclonal antibodies are used to detect Salmonella of a plurality serotypes and other strains according to sandwich ELISA, thereby obtaining a result in which Salmonella is detected serotype transversely, whereas other strains are not detected.SELECTED DRAWING: Figure 1

This invention relates to the application of the avian adenovirus serotype 4 multi-epitope recombinant chimeric protein rcF2 in the preparation of a kit for detecting avian adenovirus serotype 4 antibodies. The amino acid sequence of the avian adenovirus serotype 4 multi-epitope recombinant chimeric protein rcF2 is shown in SEQ ID NO.1. This invention utilizes the multi-epitope recombinant chimeric protein rcF2 to establish an indirect ELISA detection method and kit for detecting avian adenovirus serotype 4. This recombinant chimeric protein can be recognized by avian adenovirus serotype 4 positive sera, and the detection sensitivity of positive sera samples can reach 1:16000. It shows no cross-reactivity with antibodies against other pathogens, indicating that the ELISA detection method based on this multi-epitope recombinant chimeric protein rcF2 is simple to operate, enhances detection sensitivity, and has good specificity and repeatability.